ew Chiba Refractory Schizophrenia Treatment (CREST)-LAI study: Effectiveness of Risperidone Long-acting Injectable for Treatment-resistant Schizophrenia
Not Applicable
- Conditions
- Schizophrenia/Schizoaffective Disorder
- Registration Number
- JPRN-UMIN000011710
- Lead Sponsor
- Department of Psychiatry, Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
A)with a treatment history of RLAI injection B)under treatment with clozapine C)under ECT treatment D)with any other Axis 1 or 2 psychiatric disorder E)with clinically severe physical disease F)with pregnancy or suspected pregnancy G)a physician assessed the patient as unsuitable for participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Brief Psychiatric Rating Scale(BPRS: Overall and Gorham, 1962)
- Secondary Outcome Measures
Name Time Method Global Assessment of Functioning (GAF) Clinical Global Impression Scale-Severity/-Change Extrapyramidal Symptom Rating Scale (ESRS: Chouinard and Margolese, 2005)